BLUEPRINT MEDICINES news, videos and press releases - Page 4
For more news please use our advanced search feature.
BLUEPRINT MEDICINES - More news...
BLUEPRINT MEDICINES - More news...
- Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
- Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Blueprint Medicines Reports Second Quarter 2022 Results
- Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
- Blueprint Medicines Publishes Inaugural Corporate Responsibility Report
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC
- Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC
- Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma
- Blueprint Medicines Appoints Habib Dable to its Board of Directors
- Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis
- Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Blueprint Medicines Reports First Quarter 2022 Results
- Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
- Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer
- Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis
- Blueprint Medicines to Showcase Broad Precision Therapy Pipeline at AACR Annual Meeting 2022
- Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies
- Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results
- Blueprint Medicines to Present at Upcoming Investor Conferences
- Blueprint Medicines to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022
- Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis
- Blueprint Medicines Elevates Two Talented Leaders to its Executive Team
- Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership
- Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Blueprint Medicines Completes Acquisition of Lengo Therapeutics
